Previous 10 | Next 10 |
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will par...
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the appointments of Samik...
A clinical update from a biotech working on T-cell therapies has Evercore ISI reiterating a price target that's the highest on Wall Street. No dose-limiting toxicities or clinically relevant adverse events were reported by Cabaletta Bio (NASDAQ:CABA) in the third dosing cohort of its DSG3-CAA...
Cabaletta Bio (NASDAQ:CABA) announced 28-day data from the third dose group using 500 million DSG3-CAART cells in the DesCAARTes phase 1 trial to treat patients with mucosal-dominant pemphigus vulgaris ((mPV)), a disease causing blisters and sores on the skin or mucous mem...
Cabaletta Bio (NASDAQ:CABA): Q3 GAAP EPS of -$0.45 beats by $0.05. As of September 30, 2021, Cabaletta had cash, cash equivalents and investments of $119.3M, compared to $108.7M as of December 31, 2020. Press Release The Company expects that its cash, cash equivalents and investments as...
– Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort with 500 million DSG3-CAART cells relative to the first two low dose cohorts in DesCAARTes™ Phase 1 clinical trial throughout the 28 days following infusion – – No dos...
– Dose dependent increase in DSG3-CAART persistence observed in the third dose cohort relative to the first two low dose cohorts throughout the 28 days following infusion – – No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as ...
– Chimeric AutoAntibody Receptor (CAAR) T cells specifically recognized and eliminated anti-PLA2R antibody-expressing B cells in vitro – – Membrane proteome arrays screened with PLA2R CAAR candidates did not identify off-target interactions – ...
PHILADELPHIA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger,...
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will pa...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...